Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Anemia 1

Interventions

olaparib 9Carboplatin 3talazoparib 1pembrolizumab 1liposomal doxorubicin 1iniparib 1Trabectedin 1Surveys and Questionnaires 1Secretin 1Paclitaxel 1Genotype 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1Biopsy, Fine-Needle 1ABT-767 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × Paclitaxel × Classical hematology × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡